Swine Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Recombinant Vaccines is the fastest growing sector, Asia-Pacific is the largest market

The global swine vaccines market is set for considerable expansion, with projections indicating growth from USD 1.39 billion in 2025 to USD 1.85 billion by 2031, at a compound annual growth rate of 4.88%. Swine vaccines are biological preparations formulated to stimulate the immune system of pigs, thereby providing acquired immunity against specific pathogens. This market's growth is primarily propelled by the escalating global consumption of pork, which necessitates efficient livestock production, alongside the implementation of increasingly stringent food safety regulations aimed at controlling zoonotic risks.

Furthermore, a heightened emphasis on preventative veterinary care, crucial for minimizing the financial losses associated with disease outbreaks, significantly boosts the demand for these immunization products. With global pork production forecast to reach 116.7 million metric tons in 2025, a vast addressable market exists for veterinary health products vital for ensuring herd sustainability. However, a notable impediment to market expansion lies in the high costs and logistical complexities involved in maintaining the cold chain infrastructure required for the effective storage and distribution of these sensitive biological products, particularly within emerging economies.

Market Drivers

The increasing prevalence of transboundary and zoonotic swine diseases serves as the primary catalyst propelling the global swine vaccines market forward. The persistent spread of high-impact pathogens, such as African Swine Fever (ASF) and Porcine Reproductive and Respiratory Syndrome (PRRS), compels producers to adopt rigorous immunization schedules to safeguard herd health and economic viability. These outbreaks not only disrupt international trade but also pose significant threats to food security, necessitating immediate veterinary intervention to prevent catastrophic stock depletion.

For instance, African Swine Fever had been reported in 71 countries since January 2022, leading to over 2.2 million animal losses by November 2025, underscoring the critical reliance on prophylactic measures and driving sustained demand for effective biological countermeasures across major pork-producing regions. Concurrently, escalating R&D investments aimed at addressing novel and evolving viral strains further accelerate market development, as pharmaceutical companies endeavor to bridge gaps in immunity and vaccine efficacy.

Industry leaders are channeling substantial capital into expanding manufacturing infrastructure and scientific capabilities to combat emerging variants and improve delivery mechanisms; a notable example is Merck Animal Health's announcement in May 2025 of an $895 million expansion in Kansas specifically to boost vaccine manufacturing and research capabilities. This surge in funding facilitates the creation of next-generation solutions, although their commercial success remains closely tied to market uptake. The robust financial commitment and returns in this sector are further illustrated by Boehringer Ingelheim's Ingelvac Circoflex swine vaccine, which achieved annual sales of 215 million EUR for the 2024 financial year by April 2025.

Market Challenges

The high cost and logistical complexity inherent in maintaining cold chain infrastructure significantly impede the expansion of the Global Swine Vaccines Market, especially within emerging economies. Swine vaccines are strictly temperature-sensitive biological products that require an unbroken chain of climate-controlled storage from the point of manufacture to administration. In developing regions, where pork production is intensifying, the prevalent absence of reliable electricity and specialized logistics networks forces distributors to incur exorbitant expenses to prevent product spoilage, thereby inflating the final cost of immunization.

This financial burden often renders essential veterinary care economically inaccessible for many small-scale farmers, who constitute a crucial segment of the addressable market. Consequently, this logistical bottleneck restricts market penetration in high-growth geographic zones, effectively stalling revenue generation despite the urgent need for disease control, and correlating with sustained productivity losses that the market struggles to mitigate. According to the Food and Agriculture Organization, transboundary animal diseases were estimated to cause global economic losses of approximately USD 300 billion annually in 2024, representing a roughly 20 percent loss in total livestock production value; this data highlights the substantial market gap where infrastructure deficits prevent the effective delivery of immunization products, thereby hampering the industry's ability to capitalize on global demand.

Market Trends

Accelerated research and development for African Swine Fever (ASF) solutions is rapidly transitioning from experimental trials to the commercial deployment of viable immunizations, fundamentally altering disease management protocols in endemic regions. While biosecurity measures remain foundational, the market is witnessing the historic introduction of approved biological countermeasures into international trade, driven by the urgent necessity to protect standing herds, particularly in Southeast Asia.

This significant shift validates the scientific community's focus on live attenuated platforms to combat complex viral threats that previously lacked effective prophylaxis; for instance, demonstrating growing cross-border trust in new formulations, AVAC Vietnam Joint Stock Company exported a second batch comprising 340,000 doses of its African Swine Fever vaccine to the Philippines in September 2025 to support the country’s disease control efforts.

Simultaneously, the development of multivalent and combination vaccines is reshaping herd health strategies by prioritizing operational efficiency and animal welfare through reduced handling. Producers are increasingly adopting multi-antigen formulations that allow for simultaneous protection against diverse pathogens or multiple viral genotypes in a single administration, thereby minimizing stress-induced performance dips and lowering labor costs. This trend is compelling manufacturers to integrate broader coverage into their flagship product lines to match the evolving genetic diversity of field strains, as illustrated by Boehringer Ingelheim’s September 2025 launch of Ingelvac Circoflex AD, a novel combination vaccine specifically engineered to target the PCV2a and PCV2d genotypes responsible for over 90 percent of clinical porcine circovirus cases.

Key Market Players

• Merck & Co Inc
• Zoetis Inc
• Boehringer Ingelheim GmbH
• Elanco Animal Health Inc
• Indian Immunologicals Ltd
• Biogenesis Bago SA
• Phibro Animal Health Corp
• Laboratorios HIPRA SA
• Virbac SA

Report Scope

In this report, the Global Swine Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Swine Vaccines Market, by Product:

• Attenuated Live Vaccines
• DNA Vaccines
• Inactivated Vaccines
• Recombinant Vaccines
• Subunit Vaccines

Swine Vaccines Market, by Type:

• Actinobacillus Pleuropneumoniae
• Classical Swine Fever
• Foot & Mouth Disease
• PEDV
• Porcine Circovirus Type 2
• Porcine Parvovirus
• PRRS
• Pseudorabies
• Swine Influenza

Swine Vaccines Market, by Target Disease:

• Arthritis
• Bordetella Rhinitis
• Diarrhea
• Foot & Mouth Disease
• Porcine Circovirus Associated Disease
• Porcine Reproductive & Respiratory Syndrome
• Pseudorabies
• Swine Influenza

Swine Vaccines Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Swine Vaccines Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.